Premium
Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin®) in prostatic cancer patients
Author(s) -
Stege Reinhard,
Gunnarsson Per Olov,
Johansson CarlJohan,
Olsson Per,
Pousette Åke,
Carlström Kjell
Publication year - 1996
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(199605)28:5<307::aid-pros6>3.0.co;2-8
Subject(s) - estrone , pharmacokinetics , endocrinology , testosterone (patch) , medicine , estrone sulfate , endocrine system , intramuscular injection , castration , estrogen , chemistry , hormone
The pharmacokinetics and endocrine effects of polyestradiol phosphate (PEP; Estradurin®) were studied by determination of the concentrations of estradiol (E 2 ), unconjugated (E 1 ) and total estrone (tE 1 ; ≥85% estrone sulfate), and testosterone in serum from 11 prostatic cancer patients after administration of a single intramuscular injection (320 mg). After injection of PEP, serum concentrations of E 2 , E 1 , and tE 1 increased during 2–3 weeks. Thereafter serum E 2 declined monophasically with a mean half‐life of 70 days. The elimination of E 1 and tE 1 seemed to be governed by the formation of E 2 . The testosterone concentration decreased inversely to the raising E 2 level and reached castration levels within 3 weeks and remained at this level for about 2 weeks, whereafter it increased inversely to the decreasing E 2 concentrations. © 1996 Wiley‐Liss, Inc.